Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$73.51 USD

73.51
5,440,398

+0.21 (0.29%)

Updated Jul 18, 2024 03:55 PM ET

After-Market: $73.52 +0.01 (0.01%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Ford, Pinterest, Peloton Interactive, Gilead Sciences and T-Mobile US

The Zacks Analyst Blog Highlights: Ford, Pinterest, Peloton Interactive, Gilead Sciences and T-Mobile US

Mark Vickery headshot

Massive Q4 Earnings Beats: Ford, Pinterest, Peloton & More

There are so many companies hitting the tape with earnings reports in the after-hours, we only have time to touch on a few of them.

Gilead Sciences (GILD) Q4 Earnings and Revenues Top Estimates

Gilead (GILD) delivered earnings and revenue surprises of 1.86% and 4.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised

Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.

Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody

Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.

Will Eylea, Dupixent Drive Regeneron's (REGN) Q4 Earnings?

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports fourth-quarter 2020 results.

SAP SE (SAP) Q4 Earnings and Revenues Decline Y/Y, Stock Down

SAP SE (SAP) fourth-quarter results reflect lingering coronavirus crisis led business impacts on Concur solutions. However, gain from high demand for digital supply chain, Qualtrics and cloud platform solutions supported the top line.

Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings?

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.

Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales

Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $64.68, marking a -1.22% move from the previous day.

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.

What's in the Cards for Amgen (AMGN) This Earnings Season?

Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the fourth quarter is what remains to be seen when the company reports results.

Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?

On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta.

Lilly's (LLY) Bamlanivimab Combo Lowers COVID-19 Hospitalization

Eli Lilly's (LLY) combination of its COVID-19 antibodies bamlanivimab (LY-CoV555) plus etesevimab (LY-CoV016) reduces COVID-19-related hospitalizations and deaths by 70%.

Will Eli Lilly (LLY) Beat Estimates This Earnings Season?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.

Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes

Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.

Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?

Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.

Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar

Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.

Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

What's in Store for UnitedHealth (UNH) This Earnings Season?

UnitedHealth's (UNH) earnings results are likely to reflect solid contribution from its segments, namely Healthcare and Optum, partly offset by higher claim costs.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $63.33 in the latest trading session, marking a +1.49% move from the prior day.

Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY

The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.

Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy

Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.

Ekta Bagri headshot

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.